Tinostamustine Conditioning and Autologous Stem Cell (TITANIUM1)

You may be eligible for inclusion in the above clinical trial, which has study centres in Alabama, Kansas, New York, North Carolina, Tennessee, Texas, and Wisconsin in the USA and in Oslo, Basel, Bern, St Gallen, and Zurich in Europe. The aim of the study is to examine the effects of the novel treatment tinostamustine as conditioning therapy for those patients with relapsed or progressive multiple myeloma who are eligible to receive a second autologous stem cell transplant.

If you wish to be considered for this study, you should contact your healthcare professional and they will assess your suitability and if appropriate, refer you to the centre undertaking the trial.

To take part in this trial, you will have to meet certain requirements, which include: Age range of 18-75 years, that you have received a previous stem cell transplant, that you are not currently pregnant and/or breastfeeding and that you have not recently participated in a clinical trial.